麻豆传媒

Complete responses in 21% of patients treated with single-agent revumenib

News, features, and commentary about cancer-related issues

Improvements seen in pain, neuropathy, and cognitive function

Health news and commentary gathered by 麻豆传媒 staff

Obecabtagene autoleucel has no requirement for a REMS program

News, features, and commentary about cancer-related issues

-- News, features, and commentary about cancer-related issues

Likelihood of severe maternal morbidity more than 20 times higher versus the general population

10% of patients in trials leading to eli-cel's approval developed MDS or AML

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

Regimen tops best historical response rate with chemoimmunotherapy in this setting

Incidence almost identical to that with standard cancer treatment in randomized trials